Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits

31. January 2017
by V. Bhaskar, M. Fox, D. Breinberg, M. H. Wong, P. E. Wales, S. Rhodes, R. B. DuBridge, V. Ramakrishnan
View PDF
Reference:
V. Bhaskar, M. Fox, D. Breinberg, M. H. Wong, P. E. Wales, S. Rhodes, R. B. DuBridge, V. RamakrishnanVolociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbitsIn Invest New Drugs, volume 26, 2008.
Bibtex Entry:
@article{RN1742,
   author = {Bhaskar, V. and Fox, M. and Breinberg, D. and Wong, M. H. and Wales, P. E. and Rhodes, S. and DuBridge, R. B. and Ramakrishnan, V.},
   title = {Volociximab, a chimeric integrin alpha5beta1 antibody, inhibits the growth of VX2 tumors in rabbits},
   journal = {Invest New Drugs},
   volume = {26},
   number = {1},
   pages = {7-12},
   url = {Bhaskar Invest New Drugs 2008.pdf},
   year = {2008},
   type = {Journal Article}
}